FDA and Cancer Drug Development: An Advocate's View
This article was originally published in RPM Report
Friends of Cancer Research (www.focr.org) has been among the most vocal supporters of a robust FDA review process for oncology drugs. Chair & Founder Dr. Ellen Sigal has taken the advocacy group from a one-person shop to an organization with strong ties to the agency and the lawmakers on Capitol Hill who matter most to the future of cancer treatment.
You may also be interested in...
Current and former FDA officials and a former Big Pharma head of R&D discuss FDA and the relationship between a regulator and the industry it regulates when it comes to drug development.
The Reagan-Udall Foundation is the one piece of the FDA drug safety law enacted in 2007 that both FDA and industry are excited about. Congressional appropriators, however, have serious concerns. The stakes are higher than they seem: in the short run, the Critical Path and active surveillance systems may depend on the foundation. In the long run, the question is whether industry has any say in the evolution of regulation.
FDA is getting tougher on cancer drug approvals. But stakeholders on all sides-industry, regulators, and patient groups-say that's probably a good thing. Under the leadership of Richard Pazdur, MD, the controversial director of FDA's newly formed Office of Oncology Drug Products, the agency is raising the bar for getting cancer drugs on the market.